<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37097329</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>Prevalence and clinical significance of lymphadenopathy and its histological subtypes in patients with systemic lupus erythematosus: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>1277</StartPage><EndPage>1286</EndPage><MedlinePgn>1277-1286</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-023-05331-4</ELocationID><Abstract><AbstractText>The objective of this study was to&#xa0;evaluate the prevalence and the clinical significance of lymphadenopathy and its histological subtypes in patients with systemic lupus erythematosus. We conducted a retrospective cohort study of patients with SLE diagnosed using the 1997 ACR criteria,&#xa0;who were followed at our institution between 2008 and 2022. Patients were grouped based on the presence of SLE-attributed LAD and its histological phenotype, then compared in terms of demographic, clinical and laboratory characteristics. Of the 255 patients, 33.7% had SLE-attributed, 0.8% lymphoma-related and 0.4% tuberculosis-related LAD. Univariate analysis identified significant associations between the presence of LAD and fever (p&#x2009;&lt;&#x2009;0.0001), weight loss (p&#x2009;=&#x2009;0.009), pericarditis (p&#x2009;=&#x2009;0.004), myocarditis (p&#x2009;=&#x2009;0.003), myositis (p&#x2009;=&#x2009;0.034), leukopenia (p&#x2009;=&#x2009;0.004), lymphopenia (p&#x2009;=&#x2009;0.003), membranous nephritis (p&#x2009;=&#x2009;0.004), anti-RNP (p&#x2009;=&#x2009;0.001), anti-Smith (p&#x2009;=&#x2009;&#x2009;&lt;&#x2009;0.0001), and SSB antibodies (p&#x2009;=&#x2009;0.038), and hypocomplementemia (C3:p&#x2009;=&#x2009;0.019; C4:p&#x2009;&lt;&#x2009;0.0001). Logistic regression confirmed the associations of LAD with fever (OR&#x2009;=&#x2009;3.277, 95% C.I 1.657-6.481), pericarditis (OR&#x2009;=&#x2009;4.146, 95% C.I:1.577-10.899), membranous nephritis (OR&#x2009;=&#x2009;3.586, 95% C.I:1.305-9.854), and leukopenia (OR&#x2009;=&#x2009;2.611, 95%C.I:1.319-5.166), but not with&#xa0;weight loss, myocarditis, or myositis. Biopsy in&#xa0;a subset of patients (33.7%&#xa0;of total) revealed reactive/proliferative (62.1%) or necrotizing (37.9%) histological patterns. When we compared the histologic patterns, necrotizing LAD was associated with fever (p&#x2009;=&#x2009;0.052), sicca (p&#x2009;=&#x2009;0.018), and malar rash (p&#x2009;=&#x2009;0.005). Most patients received corticosteroids, hydroxychloroquine, and/or DMARDs with relatively quick clinical improvement. In conclusion,&#xa0;LAD is a common SLE manifestation, associated with constitutional symptoms, myo-/pericarditis, myositis, cytopenia, and membranous nephritis. Despite relatively high prevalence of LAD in SLE, a biopsy may still be needed to rule out lymphoma.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papachristodoulou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9726-7144</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Beth Israel Deaconess Medical Center, 110 Francis St, Suite 4B, Boston, MA, 02215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graef</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5973-3477</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Beth Israel Deaconess Medical Center, 110 Francis St, Suite 4B, Boston, MA, 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magliulo</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0103-1258</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Beth Israel Deaconess Medical Center, 110 Francis St, Suite 4B, Boston, MA, 02215, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lahey Hospital &amp; Medical Center, Burlington, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyttaris</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-7652-3826</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Beth Israel Deaconess Medical Center, 110 Francis St, Suite 4B, Boston, MA, 02215, USA. vkyttari@bidmc.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA. vkyttari@bidmc.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000721270">malar rash</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000092522" MajorTopicYN="N">Clinical Relevance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010493" MajorTopicYN="Y">Pericarditis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072281" MajorTopicYN="Y">Lymphadenopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007970" MajorTopicYN="Y">Leukopenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009393" MajorTopicYN="Y">Nephritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cohort studies</Keyword><Keyword MajorTopicYN="N">Lymphadenitis</Keyword><Keyword MajorTopicYN="N">Lymphadenopathy</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>25</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37097329</ArticleId><ArticleId IdType="doi">10.1007/s00296-023-05331-4</ArticleId><ArticleId IdType="pii">10.1007/s00296-023-05331-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos GC (2020) Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol 21:605&#x2013;614. https://doi.org/10.1038/s41590-020-0677-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0677-6</ArticleId><ArticleId IdType="pubmed">32367037</ArticleId><ArticleId IdType="pmc">8135909</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois EL, Tuffanelli DL (1964) Clinical manifestations of systemic lupus erythematosus: computer analysis of 520 cases. JAMA J Am Med Assoc 190:104&#x2013;111. https://doi.org/10.1001/jama.1964.03070150014003</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1964.03070150014003</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Khamashta M, Font J et al (1993) Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. The European Working Party on Systemic Lupus. Med 72:113&#x2013;124</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005792-199303000-00005</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel BA, Catoggio LJ, Cardiel MH et al (2004) The GLADEL multinational latin american prospective inception cohort of 1214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among &#x201c;Hispanics.&#x201d; Medicine 83:1&#x2013;17. https://doi.org/10.1097/01.md.0000104742.42401.e2</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000104742.42401.e2</ArticleId><ArticleId IdType="pubmed">14747764</ArticleId></ArticleIdList></Reference><Reference><Citation>Berbel A, Estevez M, Freire M et al (2018) AB0547&#x2005;lymphadenopathy in systemic lupus erythematosus: clinical relevance and histological subtypes. Ann Rheum Dis 77:1429&#x2013;1430. https://doi.org/10.1136/annrheumdis-2018-eular.4125</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-eular.4125</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapira Y, Weinberger A, Wysenbeek AJ (1996) Lymphadenopathy in systemic lupus erythematosus. Prevalence and relation to disease manifestations. Clin Rheumatol 15:335&#x2013;338. https://doi.org/10.1007/BF02230354</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02230354</ArticleId><ArticleId IdType="pubmed">8853165</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271&#x2013;1277. https://doi.org/10.1002/ART.1780251101</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ART.1780251101</ArticleId><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima M, Motoori T, Asano S, Nakamura S (2007) Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients. Pathol Res Pract 203:423&#x2013;431. https://doi.org/10.1016/j.prp.2007.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prp.2007.03.002</ArticleId><ArticleId IdType="pubmed">17540509</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima M, Nakamura S, Morishita Y et al (2000) Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases. Pathol Int 50:304&#x2013;312. https://doi.org/10.1046/J.1440-1827.2000.01052.X</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/J.1440-1827.2000.01052.X</ArticleId><ArticleId IdType="pubmed">10849316</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M et al (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4:1623&#x2013;1627. https://doi.org/10.1371/JOURNAL.PMED.0040296</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PMED.0040296</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubio J, Krishfield S, Kyttaris VC (2020) Application of the 2019 European League Against Rheumatism/American College of Rheumatology systemic lupus erythematosus classification criteria in clinical practice: a single center experience. Lupus 29:421&#x2013;425. https://doi.org/10.1177/0961203320908939</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320908939</ArticleId><ArticleId IdType="pubmed">32098572</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151&#x2013;1159. https://doi.org/10.1136/annrheumdis-2018-214819</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association (2013) Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191&#x2013;2194. https://doi.org/10.1001/JAMA.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2013.281053</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaddey HL, Riegel AM (2016) Unexplained lymphadenopathy: evaluation and differential diagnosis. Am Fam Physician 94:896&#x2013;903</Citation><ArticleIdList><ArticleId IdType="pubmed">27929264</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss LM, O&#x2019;Malley D (2013) Benign lymphadenopathies. Mod Pathol 261(26):S88&#x2013;S96. https://doi.org/10.1038/modpathol.2012.176</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/modpathol.2012.176</ArticleId></ArticleIdList></Reference><Reference><Citation>Vil&#xe1; LM, Mayor AM, Valent&#xed;n AH et al (1999) Clinical and immunological manifestations in 134 Puerto Rican patients with systemic lupus erythematosus. Lupus 8:279&#x2013;286. https://doi.org/10.1191/096120399678847803</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399678847803</ArticleId><ArticleId IdType="pubmed">10413206</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>